Ticker > Company >

Nureca share price

Nureca Ltd.

NSE: NURECA BSE: 543264 SECTOR: Medical Equipment/Supplies/Accessories  1.01 L   297   22

227.51
-1.53 (-0.67%)
NSE: Today, 04:06 PM

Price Summary

Today's High

₹ 234

Today's Low

₹ 224.02

52 Week High

₹ 343

52 Week Low

₹ 204

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

217.09 Cr.

Enterprise Value

176.4 Cr.

No. of Shares

0.95 Cr.

P/E

730.84

P/B

1.23

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  185.66

CASH

41.35 Cr.

DEBT

0.67 Cr.

Promoter Holding

68.09 %

EPS (TTM)

₹  0.31

Sales Growth

28.41%

ROE

0.16 %

ROCE

2.08%

Profit Growth

144.46 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Nureca Ltd.

Dr. Trust Dr. Physio Trumom

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year28.41%
3 Year9.57%
5 Year-7.15%

Profit Growth

1 Year144.46%
3 Year26.73%
5 Year-63.61%

ROE%

1 Year0.16%
3 Year-0.48%
5 Year3.8%

ROCE %

1 Year2.08%
3 Year0.32%
5 Year5.86%

Debt/Equity

0.0038

Price to Cash Flow

680.53

Interest Cover Ratio

3.7507

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2026 68.09 0.00
Dec 2025 68.09 0.00
Sep 2025 64.97 0.00
Jun 2025 64.33 0.00
Mar 2025 64.30 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 0.856 Cr.
  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 87.4807 days.
  • Company has a healthy liquidity position with current ratio of 7.0152.
  • The company has a high promoter holding of 68.09%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 6.11110261230742.

 Limitations

  • The company has shown a poor revenue growth of 9.57293768851855% for the Past 3 years.
  • Company has a poor ROE of -0.481466666666667% over the past 3 years.
  • Company has a poor ROCE of 0.3241% over the past 3 years
  • The company has a low EBITDA margin of -2.57498% over the past 5 years.
  • The company is trading at a high PE of 730.84.
  • The company is trading at a high EV/EBITDA of 30.7842.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 31.75 34.32 37.84 39.64 35.41
Total Expenditure 31.18 35.4 35.22 37.25 41.95
Operating Profit 0.57 -1.08 2.62 2.4 -6.54
Other Income 2 2.59 2.38 2.29 1.06
Interest 0.59 0.2 0.41 0.18 0.24
Depreciation 0.48 0.48 0.48 0.46 0.43
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.5 0.83 4.11 4.05 -6.15
Tax -0.57 0.28 0.97 0.82 0.47
Profit After Tax 2.07 0.55 3.14 3.23 -6.63
Adjusted EPS (Rs) 2.07 0.55 3.14 3.39 -6.94

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 255.55 111.9 94.52 114.64 147.21
Total Expenditure 199.78 127.29 105.67 124.64 149.81
Operating Profit 55.77 -15.39 -11.15 -10 -2.6
Other Income 7.72 7.17 10.58 12.81 8.32
Interest 0.73 0.43 0.46 1.12 1.03
Depreciation 1.43 2.3 2.24 2.15 1.85
Exceptional Items 0 0 0 0 0
Profit Before Tax 61.33 -10.96 -3.27 -0.46 2.84
Tax 16.02 -2.54 -0.83 0.21 2.54
Net Profit 45.31 -8.42 -2.44 -0.67 0.3
Adjusted EPS (Rs.) 45.31 -8.42 -2.44 -0.67 0.31

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 10 10 10 10 9.54
Total Reserves 193.74 185.26 182.86 182.48 167.62
Borrowings 0 0 0.33 1.05 0.22
Other N/C liabilities 3.59 0.11 -2.5 -1.06 -1
Current liabilities 45.14 8.62 9.27 10.44 15.91
Total Liabilities 252.48 203.98 199.96 202.91 192.29
Assets
Net Block 9.78 8.08 6.33 7.8 12.29
Capital WIP 0 0 0 0 0
Intangible WIP 0.42 0 0 0 0
Investments 1.31 3.06 3.06 3.06 3.05
Loans & Advances 0.26 1.61 0.92 3.86 0.88
Other N/C Assets 1.95 7.24 0 3.82 64.49
Current Assets 238.76 184 189.66 184.38 111.58
Total Assets 252.48 203.98 199.96 202.91 192.29
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 61.33 -10.96 -3.27 -0.46 2.84
Adjustment -3.79 -3.64 -6.98 -8.14 4.92
Changes in Assets & Liabilities -37.76 30.78 5.76 -9.19 -7.87
Tax Paid -17.96 -4.14 1.49 -1.03 0.43
Operating Cash Flow 1.83 12.05 -3 -18.82 0.32
Investing Cash Flow -3.37 -18.3 17.84 8.83 16.5
Financing Cash Flow -7.3 -1.51 -1.28 -0.79 -18.61
Net Cash Flow -8.84 -7.76 13.56 -10.77 -1.79

Corporate Actions

Investors Details

PARTICULARS Mar 2025% Jun 2025% Sep 2025% Dec 2025% Mar 2026%
promoters 64.30 64.33 64.97 68.09 68.09
aryan goyal - 7.23 7.59 12.15 12.15
nectar biopharma private ... 0.61 0.61 0.61 0.64 0.64
payal goyal - 24.60 24.60 21.59 21.59
saurabh goyal - 31.89 32.17 33.72 33.72
aryan goyal 7.23 - - - -
payal goyal 24.60 - - - -
saurabh goyal 31.86 - - - -
PARTICULARS Mar 2025% Jun 2025% Sep 2025% Dec 2025% Mar 2026%
investors 35.70 35.67 35.03 31.91 31.91
llp - 0.02 0.02 0.02 0.02
nureca limited buy back d... - - - 4.58 -
nisarg vakharia 1.78 1.85 - - -
viral amal parikh - 1.08 - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2019
Annual Report 2018

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY26
Presentation Q4FY25
Presentation Q4FY24
Presentation Q3FY26
Presentation Q3FY26
Presentation Q3FY24
Presentation Q2FY24
Presentation Q1FY22

Company News

Nureca informs about disclosure 20 Jun, 1:01 PM Nureca informs about disclosure 10 Jun, 10:04 AM Nureca Ltd. - Quaterly Results 17 Oct, 12:00 AM Nureca informs about filing of scheme 24 Jul, 1:30 PM Nureca Ltd. - Quaterly Results 15 Jul, 5:44 PM Nureca Ltd. - Quaterly Results 15 Jul, 5:44 PM Nureca Ltd. - Quaterly Results 15 Jul, 5:44 PM Nureca Ltd. - Quaterly Results 5 May, 9:03 PM Nureca Ltd. - Quaterly Results 5 May, 9:03 PM Nureca expands quick commerce reach with Dr Trust products now available on Swiggy Instamart 30 Apr, 11:41 AM Nureca gets nod to set up new manufacturing facility in Punjab 22 Apr, 12:20 PM Nureca’s manufacturing arm completes annual registration with USFDA 14 Apr, 9:09 AM Nureca informs about press release 12 Apr, 4:53 PM Nureca gets nod to purchase land in India 25 Feb, 12:12 PM Nureca informs about disclosure 31 Jan, 5:20 PM Nureca Ltd. - Quaterly Results 24 Jan, 6:16 PM Nureca Ltd. - Quaterly Results 24 Jan, 6:16 PM Nureca Ltd. - Quaterly Results 24 Jan, 6:16 PM Nureca informs about appoinemnt of additional directors 21 Nov, 1:35 PM Nureca enters into distribution agreement with Zepto 16 Nov, 3:20 PM Nureca Ltd. - Quaterly Results 24 Oct, 5:47 PM Nureca Ltd. - Quaterly Results 24 Oct, 5:47 PM Nureca informs about closure of trading window 26 Sep, 4:26 PM Nureca enters into distribution agreement to make products available on commerce platform 17 Sep, 12:42 PM Nureca Ltd. - Quaterly Results 5 Aug, 5:11 PM Nureca Ltd. - Quaterly Results 5 Aug, 5:11 PM Nureca Ltd. - Quaterly Results 5 Aug, 5:11 PM Nureca Ltd. - Quaterly Results 15 May, 11:51 AM Nureca Ltd. - Quaterly Results 15 May, 11:51 AM Nureca Ltd. - Quaterly Results 15 May, 11:51 AM Nureca informs about compliance certificate 9 Apr, 2:17 PM Nureca’s Dr Trust recognized as ‘Well Known Trademark’ by Indian Trademark Registry 2 Apr, 6:07 PM Nureca informs about press release 1 Mar, 1:24 PM Nureca informs about press release 8 Feb, 5:02 PM Nureca Ltd. - Quaterly Results 7 Feb, 5:24 PM Nureca Ltd. - Quaterly Results 7 Feb, 5:24 PM Nureca Ltd. - Quaterly Results 7 Feb, 5:24 PM Nureca Ltd. - Quaterly Results 4 Nov, 5:17 PM Nureca Ltd. - Quaterly Results 4 Nov, 5:17 PM Nureca Ltd. - Quaterly Results 4 Nov, 5:17 PM Nureca Ltd. - Quaterly Results 10 Aug, 5:55 PM Nureca Ltd. - Quaterly Results 10 Aug, 5:55 PM Nureca Ltd. - Quaterly Results 23 May, 8:01 PM Nureca Ltd. - Quaterly Results 23 May, 8:01 PM Nureca informs about secretarial compliance report 17 May, 5:08 PM Nureca Ltd. - Quaterly Results 3 Feb, 6:28 PM Nureca Ltd. - Quaterly Results 3 Feb, 6:28 PM Nureca informs about board meeting 28 Jan, 12:33 PM Nureca informs about disclosure of related party transactions 26 Nov, 3:20 PM Nureca Ltd. - Quaterly Results 11 Nov, 6:38 PM

Nureca Stock Price Analysis and Quick Research Report. Is Nureca an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Nureca. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Nureca has a PE ratio of 731.127529714102 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Nureca has ROA of 0.1503% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Nureca has a Current ratio of 7.0152.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Nureca has a ROE of 0.1607%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Nureca has a Debt to Equity ratio of 0.0038 which means that the company has low proportion of debt in its capital.

  • Sales growth: Nureca has reported revenue growth of 28.4107% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Nureca for the current financial year is -1.7689015691869%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Nureca is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Nureca is Rs 0.3113. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Nureca in Ticker for free. Also, one can get the intrinsic value of Nureca by using Valuation Calculators, which are available with a Finology ONE subscription. 

Nureca FAQs

Q1. What is Nureca share price today?
Ans: The current share price of Nureca is Rs 227.6.

Q2. What is the market capitalisation of Nureca?
Ans: Nureca has a market capitalisation of Rs 217.1740992 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Nureca?
Ans: The PE ratio of Nureca is 731.127529714102 and the P/B ratio of Nureca is 1.22586444718415, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Nureca share?
Ans: The 52-week high share price of Nureca is Rs 343, and the 52-week low share price of Nureca is Rs 204.

Q5. Does Nureca pay dividends?
Ans: Currently, Nureca does not pay dividends. Dividend yield of Nureca is around 0%.

Q6. What are the face value and book value of Nureca shares?
Ans: The face value of Nureca shares is Rs 10, while the book value per share of Nureca is around Rs 185.6649. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Nureca?
Ans: Nureca has a total debt of Rs 0.667 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Nureca?
Ans: The ROE of Nureca is 0.1607% and ROCE of Nureca is 2.08%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Nureca a good buy for the long term?
Ans: The Nureca long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Nureca undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Nureca appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Nureca’s financials?
Ans: You can review Nureca’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Nureca
X